DOI: https://doi.org/10.14710/gjec.2026.31706

Molecular Docking, ADMET, and Multi-Parameter Optimization (MPO) of Punicalagin-Related Compounds as ADAM17/TACE Modulators Candidate

*Mukhammad Asy'ari orcid scopus  -  Universitas Diponegoro, Indonesia
Ariztha Delivia Putri orcid  -  Universitas Diponegoro, Indonesia
Parsaoran Siahaan orcid scopus  -  Universitas Diponegoro, Indonesia
Open Access Copyright 2026 Greensphere: Journal of Environmental Chemistry

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Citation Format:
Abstract

ADAM17/TACE is an important target in the regulation of inflammatory responses; however, the development of selective modulators remains challenging because conventional approaches generally focus on the catalytic site. Punicalagin-related compounds have been reported to possess potential as metalloprotease modulators, yet the relationship between molecular structure, binding affinity, and pharmacokinetic properties has not been comprehensively investigated. This study aimed to evaluate punicalagin-related compounds including punicalagin (PNG), punicalin (PNL), ellagic acid (ELA), gallic acid (GAA), hexahydroxydiphenic acid (HPA), shikimic acid (SKA), 3-dehydroshikimate (DHS), 3,4-dihydroxybenzoate (DXB), and marimastat (MRM) as a reference inhibitor through an integrated in silico approach involving molecular docking, physicochemical descriptor and drug-likeness analysis, ADMET prediction, and multi-parameter optimization (MPO). This approach also supports green chemistry principles through more efficient early-stage screening of bioactive candidates by reducing the use of reagents and preliminary biological experiments. Docking results showed that PNG and PNL exhibited high binding affinities (−8.2 to −8.8 kcal/mol), but with limitations in membrane penetration, whereas HPA, ELA, and GAA demonstrated moderate affinities with more favorable pharmacokinetic profiles. Physicochemical descriptor and ADMET analyses indicated that smaller metabolites fulfilled drug-likeness criteria and exhibited better bioavailability than larger ellagitannins. MPO evaluation highlighted HPA (0.65) and ELA (0.62) as promising initial candidates with an optimal balance between target interaction and pharmacokinetic feasibility.

Fulltext View|Download Email colleagues
Keywords: ADAM17/TACE; punicalagin-related; molecular docking; drug-likeness; multi-parameter optimization
Funding: Universitas Diponegoro under contract 222-502/UN7.D2/PP/IV/2025

Article Metrics:

Article Info
Section: Articles
Language : EN
  1. References
  2. T. M. de Queiroz, N. Lakkappa, and E. Lazartigues, “ADAM17-Mediated Shedding of Inflammatory Cytokines in Hypertension,” 2020. doi: 10.3389/fphar.2020.01154
  3. Y. W. Duan, S. X. Chen, Q. Y. Li, and Y. Zang, “Neuroimmune Mechanisms Underlying Neuropathic Pain: The Potential Role of TNF-α-Necroptosis Pathway,” 2022. doi: 10.3390/ijms23137191
  4. H. J. Kim et al., “ADAM17 genetic variants and the response of TNF-α inhibitor in rheumatoid arthritis patients,” Pharmgenomics. Pers. Med., vol. 13, 2020, doi: 10.2147/PGPM.S235035
  5. G. van Loo and M. J. M. Bertrand, “Death by TNF: a road to inflammation,” 2023. doi: 10.1038/s41577-022-00792-3
  6. M. Tatsumi et al., “Ectodomain shedding of EGFR ligands serves as an activation readout for TRP channels,” PLoS One, vol. 18, no. 1 January, 2023, doi: 10.1371/journal.pone.0280448
  7. N. Schumacher and S. Rose-John, “ADAM17 orchestrates Interleukin-6, TNFα and EGF-R signaling in inflammation and cancer,” Biochim. Biophys. Acta Mol. Cell Res., vol. 1869, no. 1, 2022, doi: 10.1016/j.bbamcr.2021.119141
  8. L. Gao, L. Li, D. Zhang, J. Qiu, J. Qian, and H. Liu, “TAPI-1 Exhibits Anti-tumor Efficacy in Human Esophageal Squamous Cell Carcinoma Cells via Suppression of NF-κB Signaling Pathway,” Dig. Dis. Sci., vol. 69, no. 1, pp. 81–94, Jan. 2024, doi: 10.1007/s10620-023-08181-z
  9. M. Calligaris et al., “Strategies to Target ADAM17 in Disease: From Its Discovery to the iRhom Revolution,” Molecules, vol. 26, no. 4, p. 944, Feb. 2021, doi: 10.3390/molecules26040944
  10. M. Bienstein, D. Minond, U. Schwaneberg, M. D. Davari, and D. Yildiz, “In Silico and Experimental ADAM17 Kinetic Modeling as Basis for Future Screening System for Modulators,” Int. J. Mol. Sci., vol. 23, no. 3, 2022, doi: 10.3390/ijms23031368
  11. D. Minond, “Novel Approaches and Challenges of Discovery of Exosite Modulators of a Disintegrin and Metalloprotease 10,” 2020. doi: 10.3389/fmolb.2020.00075
  12. L. Yang, C. Fan, T. Shu, and S. Wang, “Punicalin alleviates TNF‐α‐ and IL‐1β‐induced chondrocyte dysfunction and cartilage metabolism via mediating FOXO3 signaling axis,” J. Food Biochem., vol. 45, no. 8, Aug. 2021, doi: 10.1111/jfbc.13755
  13. Y. Cao, J. Chen, G. Ren, Y. Zhang, X. Tan, and L. Yang, “Punicalagin Prevents Inflammation in LPS- Induced RAW264.7 Macrophages by Inhibiting FoxO3a/Autophagy Signaling Pathway,” Nutrients, vol. 11, no. 11, p. 2794, Nov. 2019, doi: 10.3390/nu11112794
  14. M. Čolić et al., “Immunomodulatory Activity of Punicalagin, Punicalin, and Ellagic Acid Differs from the Effect of Pomegranate Peel Extract,” Molecules, vol. 27, no. 22, p. 7871, Nov. 2022, doi: 10.3390/molecules27227871
  15. V. Caballero, M. Estévez, F. A. Tomás-Barberán, D. Morcuende, I. Martín, and J. Delgado, “Biodegradation of Punicalagin into Ellagic Acid by Selected Probiotic Bacteria: A Study of the Underlying Mechanisms by MS-Based Proteomics,” J. Agric. Food Chem., vol. 70, no. 51, 2022, doi: 10.1021/acs.jafc.2c06585
  16. S. D. Home and S. Dallakyan, “Small-Molecule Library Screening by Docking with PyRx,” Methods in Molecular Biology, vol. 1263, 2015
  17. O. Trott and A. J. Olson, “AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading,” J. Comput. Chem., vol. 31, no. 2, 2010, doi: 10.1002/jcc.21334
  18. D. S. BIOVIA, “Discovery Studio Visualizer v21.1.0.20298,” BIOVIA, Dassault Systèmes, 2005
  19. E. F. Pettersen et al., “UCSF Chimera - A visualization system for exploratory research and analysis,” J. Comput. Chem., vol. 25, no. 13, 2004, doi: 10.1002/jcc.20084
  20. A. T. Nchinda and K. Menzel, “Optimizing Drug Discovery in Resource-Limited Settings: Multi-Parameter Optimization and Data-Driven Workflows,” ACS Med. Chem. Lett., 2026, doi: 10.1021/acsmedchemlett.5c00501
  21. V. Ivanović, M. Rančić, B. Arsić, and A. Pavlović, “Lipinski’s rule of five, famous extensions and famous exceptions,” Chemia Naissensis, vol. 3, no. 1, 2020, doi: 10.46793/chemn3.1.171i
  22. R. Ani, P. S. Anand, B. Sreenath, and O. S. Deepa, “In silico prediction tool for drug-likeness of compounds based on ligand based screening,” International Journal of Research in Pharmaceutical Sciences, vol. 11, no. 4, 2020, doi: 10.26452/ijrps.v11i4.3310
  23. A. Caminero Gomes Soares, G. H. Marques Sousa, R. L. Calil, and G. H. Goulart Trossini, “Absorption matters: A closer look at popular oral bioavailability rules for drug approvals,” Mol. Inform., vol. 42, no. 11, 2023, doi: 10.1002/minf.202300115
  24. A. Seelig, “P-Glycoprotein: One Mechanism, Many Tasks and the Consequences for Pharmacotherapy of Cancers,” 2020. doi: 10.3389/fonc.2020.576559
  25. D. E. V. Pires, T. L. Blundell, and D. B. Ascher, “pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures,” J. Med. Chem., vol. 58, no. 9, pp. 4066–4072, May 2015, doi: 10.1021/ACS.JMEDCHEM.5B00104
  26. A. Daina, O. Michielin, and V. Zoete, “SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules,” Scientific Reports 2017 7:1, vol. 7, no. 1, pp. 42717-, Mar. 2017, doi: 10.1038/srep42717
  27. B. Testa, A. Pedretti, and G. Vistoli, “Reactions and enzymes in the metabolism of drugs and other xenobiotics,” Drug Discov. Today, vol. 17, no. 11–12, pp. 549–560, Jun. 2012, doi: 10.1016/J.DRUDIS.2012.01.017
  28. H. Yang et al., “admetSAR 2.0: web-service for prediction and optimization of chemical ADMET properties,” Bioinformatics, vol. 35, no. 6, pp. 1067–1069, Mar. 2019, doi: 10.1093/BIOINFORMATICS/BTY707
  29. M. D. Segall, “Multi-parameter optimization: identifying high quality compounds with a balance of properties,” Curr. Pharm. Des., vol. 18, no. 9, pp. 1292–1310, Feb. 2012, doi: 10.2174/138161212799436430
  30. L. D. Pennington and I. Muegge, “Holistic drug design for multiparameter optimization in modern small molecule drug discovery,” Bioorg. Med. Chem. Lett., vol. 41, p. 128003, Jun. 2021, doi: 10.1016/J.BMCL.2021.128003
  31. O. Nicolotti, I. Giangreco, A. Introcaso, F. Leonetti, A. Stefanachi, and A. Carotti, “Strategies of multi-objective optimization in drug discovery and development,” Expert Opin. Drug Discov., vol. 6, no. 9, pp. 871–884, Sep. 2011, doi: 10.1517/17460441.2011.588696
  32. F. Aghahosseini, M. Bayat, Z. Sadeghian, D. Gheidari, and F. Safari, “Synthesis, molecular docking study, MD simulation, ADMET, and drug likeness of new thiazolo[3,2-a]pyridine-6,8-dicarbonitrile derivatives as potential anti-diabetic agents,” PLoS One, vol. 19, no. 9, p. e0306973, Sep. 2024, doi: 10.1371/JOURNAL.PONE.0306973
  33. K. El Khatabi, I. Aanouz, M. Alaqarbeh, M. A. Ajana, T. Lakhlifi, and M. Bouachrine, “Molecular docking, molecular dynamics simulation, and ADMET analysis of levamisole derivatives against the SARS-CoV-2 main protease (MPro),” Bioimpacts, vol. 12, no. 2, p. 107, Feb. 2021, doi: 10.34172/BI.2021.22143
  34. P. R. dos Santos Correia, A. H. D. de Souza, A. R. Chaparro, A. Y. Tenorio Barajas, and R. S. Porto, “Molecular Docking, ADMET Analysis and Molecular Dynamics (MD) Simulation to Identify Synthetic Isoquinolines as Potential Inhibitors of SARS-CoV-2 MPRO,” Curr. Comput. Aided. Drug Des., vol. 19, no. 5, pp. 391–404, Jan. 2023, doi: 10.2174/1573409919666230123150013
  35. A. H. Bakheit, M. W. Attwa, A. A. Kadi, H. A. Ghabbour, and H. M. Alkahtani, “Exploring the Chemical Reactivity, Molecular Docking, Molecular Dynamic Simulation and ADMET Properties of a Tetrahydrothienopyridine Derivative Using Computational Methods,” Crystals 2023, Vol. 13, Page 1020, vol. 13, no. 7, p. 1020, Jun. 2023, doi: 10.3390/CRYST13071020
  36. M. Moussaoui et al., “QSAR, ADMET, molecular docking, and dynamics studies of 1,2,4-triazine-3(2H)-one derivatives as tubulin inhibitors for breast cancer therapy,” Sci. Rep., vol. 14, no. 1, p. 16418, Dec. 2024, doi: 10.1038/S41598-024-66877-2

Last update:

No citation recorded.

Last update:

No citation recorded.